Sugi Predict

Sugi Predict / Compounds / SCHEMBL1443382

SCHEMBL1443382

SCHEMBL1443382

O=CC1CCN(c2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MBTD1 Q05BQ5 1/20 0.52
▸ L3MBTL3 Q96JM7 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ NOTUM Q6P988 1/20 0.49
▸ HTR3E A5X5Y0 1/20 0.45
▸ HTR3B O95264 1/20 0.45
▸ ADRB1 P08588 1/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ HTR3D Q70Z44 1/20 0.45
▸ HTR3C Q8WXA8 1/20 0.45
▸ SIGMAR1 Q99720 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ GRIN2B Q13224 1/20 0.43
▸ TFPI2 P48307 1/20 0.43
▸ GFER P55789 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CHRNB2 P17787 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4940215 0.82 TRIM24 (0.66) L3MBTL3L3MBTL1ALDH1A1TRIM24TRIM33
SCHEMBL3895823 0.81 CHKA (0.53) ALDH1A1CYP3A4TRIM24TRIM33TSHR
SCHEMBL1814706 0.81 NOTUM (0.50) NOTUMLMNAGFERALDH1A1MAPT
SCHEMBL20231015 0.81 TRIM24 (0.44) L3MBTL3L3MBTL1ALDH1A1MAPTTRIM24
SCHEMBL17121346 0.81 ALDH1A1 (0.50) L3MBTL3L3MBTL1LMNAGFERALDH1A1
SCHEMBL918570 0.81 NOTUM (0.50) NOTUMHTR3EHTR3BADRB1HTR3A
SCHEMBL12800742 0.80 USP2 (0.66) MBTD1L3MBTL3L3MBTL1LMNAALDH1A1
Hydrochloric Acid SCHEMBL2366509 0.79 NOTUM (0.49) NOTUMHTR3EHTR3BADRB1HTR3A
Hydrochloric Acid SCHEMBL2366337 0.79 ADRB1 (0.47) L3MBTL3L3MBTL1ADRB1LMNAALDH1A1
Hydrochloric Acid SCHEMBL1818467 0.79 NOTUM (0.49) NOTUMLMNAGFERALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 — — US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 — — EP disclosed
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS INC. (CA) 2026-01-20 — — US disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 — — CN disclosed
CN-117813307-A Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof 新锐思生物制药股份有限公司 2024-04-02 — — CN disclosed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US disclosed
WO-2023139199-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-07-27 — — WO disclosed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP disclosed
CN-115803025-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-14 — — CN disclosed
WO-2022235715-A1 COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed
US-5169096-A Serotonin antagonists, analgesics MERRELL DOW PHARMACEUTICALS INC. (US) 1992-12-08 — — US disclosed
US-5162342-A USE OF 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS FOR ANALGESIA AND MUSCLE RELAXATION MERRELL DOW PHARMACEUTICALS INC. (US) 1992-11-10 — — US disclosed
CN-1015460-B Process for preparing derivatives of asymmetric esters of 1, 4-dihydropyridine-3, 5-dicarboxylic acid SORI SOC RECH IND (FR) 1992-02-12 — — CN disclosed
US-5064838-A 1,4-DISUBSTITUTED-PIPERIDINYL COMPOUNDS AS PAIN RELIEVERS MERRELL DOW PHARMACEUTICALS (US) 1991-11-12 — — US disclosed
US-5021428-A Novel chemical compounds for the prophylactic treatment of migraine MERRELL DOW PHARMACEUTICALS INC. (US) 1991-06-04 — — US disclosed
US-4912117-A Therapy for varient angina MERRELL DOW PHARMACEUTICALS INC. (US) 1990-03-27 — — US disclosed
CN-1035823-A 1, the 4-Disubstituted-piperidnyl compounds MERRELL DOW PHARMA (US) 1989-09-27 — — CN disclosed
EP-0325268-A1 1,4-Disubstituted-piperidinyl compounds MERRELL DOW PHARMACEUTICALS INC. (US) 1989-07-26 — — EP disclosed
US-4783471-A N-aralkyl piperidine methanol derivatives and the uses thereof MERRELL DOW PHARMACEUTICALS INC. (US) 1988-11-08 — — US disclosed
CN-87102452-A 1, the derivative of the asymmetric ester of 4-dihydropyridine-3,5-dicarboxylic acid — 1987-10-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA MBTD1 3223/4885L3MBTL3 2337/4885L3MBTL1 1541/4885
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, GAA MBTD1 2548/4885L3MBTL3 2143/4885L3MBTL1 1322/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 MBTD1 2857/4885L3MBTL3 1419/4885L3MBTL1 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.